Core Viewpoint - The company reported a significant loss for the mid-2025 period, primarily due to unrealized losses on convertible bond investments, contrasting with a profit in the same period of 2024 [1] Financial Performance - The group recorded revenue of approximately 28 million HKD during the mid-2025 period [1] - Loss from continuing operations amounted to about 459 million HKD, compared to a profit of approximately 102 million HKD in the mid-2024 period [1] - The unrealized loss on convertible bond investments was approximately 443 million HKD, classified as other receivables as of September 30, 2025, which is a non-cash item [1] - In the mid-2024 period, the same investment recorded a fair value gain of about 110 million HKD [1] Industry Outlook - The Chinese pharmaceutical market is expected to achieve healthy growth driven by evolving demand for quality medical services and diversified pharmaceutical supply amid structural transformation led by national healthcare reform policies [1] - Despite facing challenges such as strict regulations and intense competition, the company believes there are potential development opportunities in the expanding consumer base within the Chinese pharmaceutical market [1] - The company plans to continuously monitor market trends and explore potential collaborations with strategic partners to develop pharmaceutical and health-related products, aiming to promote long-term development [1]

Core Viewpoint - The company reported a significant decline in revenue and a shift from profit to loss in its interim results for the six months ending September 30, 2025 [1] Financial Performance - Revenue for the period was HKD 28.08 million, representing a year-on-year decrease of 9.04% [1] - The company recorded a loss attributable to shareholders of HKD 460 million, a shift from profit to loss compared to the previous year [1] - Earnings per share were reported at a loss of HKD 0.1909 [1]

Core Points - The company reported a revenue of HKD 28.08 million for the six months ending September 30, 2025, representing a year-on-year decrease of 9.04% [1] - The company experienced a loss attributable to shareholders of HKD 460 million, marking a shift from profit to loss compared to the previous year [1] - The loss per share was HKD 0.1909 [1]

Financial Performance - The company reported a revenue of HKD 28,008,000 for the six months ended September 30, 2025, a decrease of 9.1% compared to HKD 30,792,000 in the same period last year[5]. - The gross profit for the same period was HKD 12,270,000, representing a gross margin of approximately 43.8%[5]. - The company incurred a loss from continuing operations of HKD 459,709,000, compared to a profit of HKD 100,978,000 in the previous year[6]. - The company reported a total comprehensive loss of HKD 456,863,000 for the period, compared to a comprehensive income of HKD 103,910,000 in the previous year[6]. - The basic and diluted loss per share from continuing operations was HKD (19.09), compared to earnings of HKD 4.22 in the same period last year[6]. - The company reported a net loss of HKD 459,319,000 for the six months ended September 30, 2025, compared to a profit of HKD 101,459,000 in the same period of 2024[29]. - The company did not declare an interim dividend for the six months ending September 30, 2025, compared to no dividend declared for the same period in 2024[36]. Assets and Liabilities - Total assets decreased to HKD 1,098,039,000 from HKD 1,526,352,000 as of March 31, 2025, reflecting a decline of 28%[4]. - Current assets dropped significantly to HKD 641,436,000 from HKD 1,062,791,000, a decrease of 39.5%[4]. - The company's equity attributable to owners decreased to HKD 892,643,000 from HKD 1,334,542,000, a decline of 33.1%[4]. - The company’s total liabilities as of September 30, 2025, included trade payables of HKD 4,633,000, an increase from HKD 4,427,000 as of March 31, 2025[25]. - The total debt to total assets ratio was 0.14 as of September 30, 2025, compared to 0.09 on March 31, 2025[59]. Business Operations - The company has ceased its gene development business, focusing on its manufacturing and trading operations[8]. - The group operates in three main segments: manufacturing, trade, and gene development[10]. - Revenue from the manufacturing of pharmaceuticals for the six months ended September 30, 2025, was HKD 28,000,000, a decrease of 9.1% from HKD 30,772,000 in the same period of 2024[26]. - The company’s external customer revenue from the trading of pharmaceuticals was HKD 8,000 for the six months ended September 30, 2025, down from HKD 20,000 in 2024[26]. Investments and Financial Instruments - The convertible bond investment from Star Chain Group, originally issued at HKD 715,000,000, has been reclassified as other receivables due to non-conversion[15][20]. - The fair value of the convertible bond investment was HKD 915,436,000 as of March 31, 2025, but was reclassified to zero as of September 30, 2025[16][20]. - The fair value change of convertible bonds investment for the six months ended September 30, 2025, was a loss of HKD 442,729,000, compared to a gain of HKD 111,229,000 in the same period of 2024[30]. - The company recorded an unrealized loss of approximately HKD 442.7 million related to the fair value changes of the convertible bond investment during the first half of 2025[53]. Shareholder Activities - The company issued 160,000,000 new ordinary shares at a subscription price of HKD 0.097 per share, raising a total of HKD 15,520,000[23]. - Approximately 70% of the net proceeds will be allocated to startup costs in the healthcare sector, including product development and marketing, while the remaining 30% will be reserved for working capital[62]. - As of September 30, 2025, the net proceeds from the subscription had not yet been utilized[63]. - The number of share options available under the share option scheme as of September 30, 2025, was 239,000,000, representing about 10% of the issued shares prior to the recent subscription[66]. Employee and Operational Costs - The total employee costs for the six months ending September 30, 2025, amounted to HKD 9,848,000, a decrease of 9.9% from HKD 10,936,000 in the previous year[31]. - Sales costs for the same period were HKD 15,738,000, down 17.8% from HKD 18,980,000 in the prior year[31]. - The group’s administrative, sales, and distribution expenses totaled approximately HKD 16,400,000, an increase of about HKD 1,700,000 or 11.3% compared to HKD 14,800,000 in the prior period, driven by increased marketing and promotional expenses[42]. - Employee costs for the mid-year period amounted to approximately HKD 9,800,000, a decrease from HKD 10,900,000 in the previous period, primarily due to reduced performance-related bonuses[65]. Future Outlook and Strategic Plans - The company plans to commercialize its product in Q1 2026, but has revised the timeline to around Q3 2028 due to delays in patient recruitment and clinical trials[50]. - The company aims to explore new business opportunities in the healthcare sector, driven by factors such as an aging population and increasing consumer focus on preventive healthcare[64]. - The company plans to enter two new markets by the end of 2024, targeting a 30% market share[75]. Compliance and Governance - The interim financial data was approved for publication by the board on November 28, 2025[8]. - The audit committee has reviewed the unaudited interim financial information and confirmed compliance with current accounting practices in Hong Kong[72]. - The interim results announcement has been published on the Hong Kong Stock Exchange website and the company's website[73].

Major Events - Sanofi Pharmaceutical (01530) proposes to spin off Mandi International and independently list it on the main board of the Hong Kong Stock Exchange [1] - Youbao Online (02429) signs a trusted asset management platform service agreement with Ant Chain Technology [1] - Jianxi Technology-B (09877) reports 6-month clinical follow-up results for LuX-Valve Plus TRINITY study on patients with large valve rings [1] - Fuhong Hanlin (02696) announces that Hanshu® (Sru Li monoclonal antibody injection) combined with chemotherapy for gastric cancer neoadjuvant/adjuvant treatment has been officially included in the breakthrough therapy drug program by the National Medical Products Administration [1] - Kaizhile International (02122) partners with globally renowned toy company Jazwares to launch HELLO KITTY AND FRIENDS toys [1] Operating Performance - ZTO Express-W (02057) reports third-quarter net profit attributable to shareholders of 2.524 billion yuan, an increase of 5.32% year-on-year [1] - Lenovo Group (00992) announces interim results with a profit attributable to shareholders of 846 million USD, a year-on-year growth of 40% [1] - CSPC Pharmaceutical Group (01093) releases third-quarter results showing a profit attributable to shareholders of 3.511 billion yuan, a decrease of 7.06% year-on-year [1] - NetEase-S (09999) reports third-quarter net profit attributable to shareholders of approximately 8.616 billion yuan, a year-on-year increase of 31.77%, with a dividend of 0.114 USD per share [1] - Jingyou Pharmaceutical (00858) issues a profit warning, expecting a mid-term loss of approximately 450 million to 480 million HKD, transitioning from profit to loss year-on-year [1]

Core Viewpoint - The company, 精优药业 (00858), anticipates a loss of approximately HKD 450 million to HKD 480 million for the six months ending September 30, 2025, contrasting with a profit for the same period in 2024 [1] Financial Performance - The expected loss is primarily attributed to unrealized losses on the fair value of the company's convertible bond investments, whereas the corresponding period in 2024 recorded gains from fair value changes [1] - The unrealized losses are non-cash in nature [1] Operational Stability - The company's operational performance remains stable during the current period [1]

Core Viewpoint - The company, 精优药业 (00858), anticipates a loss of approximately HKD 450 million to HKD 480 million for the six months ending September 30, 2025, contrasting with a profit for the same period in 2024 [1] Financial Performance - The expected loss is primarily attributed to unrealized losses on the fair value of the company's convertible bond investments, whereas the corresponding period in 2024 recorded gains from fair value changes [1] - The unrealized loss is classified as non-cash in nature [1] Operational Stability - The company's operational performance remains stable during the current period [1]

Core Viewpoint - Jingyou Pharmaceutical (00858.HK) anticipates a loss between HKD 450 million and HKD 480 million for the six months ending September 30, 2025, contrasting with a profit recorded in the same period of 2024 [1] Financial Performance - The expected loss is primarily attributed to unrealized losses on the fair value of the company's convertible bond investments, whereas the same project recorded fair value gains in the corresponding period of 2024 [1] - The unrealized loss is characterized as non-cash in nature [1] Operational Stability - The company's operational performance remains stable during the current period [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 （ 於百慕達註冊成立之有限公司） （股份代號：00858） 本公司仍在編製本集團截至二零二五年九月三十日止六個月之中期業績，上文所載資料僅 根據董事會目前可獲取之資料（ 包括管理賬目 ）之初步評估，其仍有待確實。本集團截至二 零二五年九月三十日止六個月之未經審核綜合中期業績預期將於二零二五年十一月底前公 佈。 股東及潛在投資者在買賣本公司股份時務請審慎行事。 承董事會命 精優藥業控股有限公司 主席 謝毅 香港，二零二五年十一月二十日 於 本 公 告 日 期 ， 執 行 董 事 為 謝 毅 博 士 、 程 勇 先 生 、 樓 屹 博 士 、 王 秀 娟 女 士 及 郭 懿 博 士 ， 獨 立 非 執 行 董 事 為 方林虎先生、金松女士及曾立博士。 盈利警報 本公告乃由精優藥業控股有限公司（「本公司」，連同其附屬公司稱為「本集團」）根據香港聯 合交易所有限公司證券上市規則（「上市規則」）第13.09條及證 ...

Core Points - The company, 精优药业 (00858.HK), has announced that its board meeting will take place on November 28, 2025, to approve the interim results for the six months ending September 30, 2025, and to address other matters if necessary [1] Group 1 - The board meeting is scheduled for November 28, 2025 [1] - The meeting will focus on approving the interim results for the six months ending September 30, 2025 [1] - Other matters may also be addressed during the meeting [1]